Thieme E-Books & E-Journals -
Synlett 2013; 24(3): 323-326
DOI: 10.1055/s-0032-1317919
cluster
© Georg Thieme Verlag Stuttgart · New York

Process Development of Halaven®: Synthesis of the C1–C13 Fragment from d-(–)-Gulono-1,4-lactone

Authors

  • Charles E. Chase

    Pharmaceutical Science & Technology, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810-2441, USA   Fax: +1(978)7944910   Email: Bryan_Lewis@eisai.com
  • Francis G. Fang

    Pharmaceutical Science & Technology, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810-2441, USA   Fax: +1(978)7944910   Email: Bryan_Lewis@eisai.com
  • Bryan M. Lewis*

    Pharmaceutical Science & Technology, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810-2441, USA   Fax: +1(978)7944910   Email: Bryan_Lewis@eisai.com
  • Gordon D. Wilkie

    Pharmaceutical Science & Technology, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810-2441, USA   Fax: +1(978)7944910   Email: Bryan_Lewis@eisai.com
  • Matthew J. Schnaderbeck

    Pharmaceutical Science & Technology, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810-2441, USA   Fax: +1(978)7944910   Email: Bryan_Lewis@eisai.com
  • Xiaojie Zhu

    Pharmaceutical Science & Technology, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810-2441, USA   Fax: +1(978)7944910   Email: Bryan_Lewis@eisai.com